Last update Dec. 12, 2022

Mebeverine Hydrochloride

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Antispasmodic drug with direct effect on intestinal smooth muscle and little anticholinergic effects. Used for treatment of Irritable Bowel Syndrome.  Oral administration three times a day.

At latest update no published data on excretion into breast milk were found.

Although antimuscarinics can decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.

During breastfeeding it may be prudent to avoid it or take a minimum dose over short periods of time, monitoring the production of milk, especially in the first weeks postpartum.

Alternatives

  • Otilonium Bromide (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Mebeverine Hydrochloride in other languages or writings:

Group

Mebeverine Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Mebeverine Hydrochloride in its composition:

List of 12 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 466 daltons
Protein Binding 75 %
Tmax 1 - 3 hours
T½ 1. 1 - 2.5 hours

References

  1. AEMPS. Mebeverina. Ficha técnica. 2008 Full text (in our servers)
  2. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002 Abstract
  3. Müller EE, Locatelli V, Cella S, Peñalva A, Novelli A, Cocchi D. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983 Apr;25(4):399-432. Review. Abstract
  4. Masala A, Alagna S, Devilla L, Rovasio PP, Rassa S, Faedda R, Satta A. Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man. J Endocrinol Invest. 1982 Jan-Feb;5(1):53-5. Abstract

Total visits

42,272

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM